Serena Fasano
Overview
Explore the profile of Serena Fasano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruscitti P, Allanore Y, Baldini C, Barilaro G, Bartoloni Bocci E, Bearzi P, et al.
Autoimmun Rev
. 2024 Jul;
23(7-8):103581.
PMID: 39069240
Inflammatory rheumatic diseases are different pathologic conditions associated with a deregulated immune response, codified along a spectrum of disorders, with autoinflammatory and autoimmune diseases as two-end phenotypes of this continuum....
2.
Tani C, Cardelli C, Zen M, Moroni L, Piga M, Ceccarelli F, et al.
J Rheumatol
. 2024 Jul;
51(11):1096-1101.
PMID: 38950957
Objective: To report real-world experience on the use of anifrolumab (ANI) in refractory systemic lupus erythematosus (SLE). Methods: The present study is a multicenter, retrospective study involving 9 Italian SLE...
3.
Zen M, Gatto M, Depascale R, Regola F, Fredi M, Andreoli L, et al.
J Pers Med
. 2023 Apr;
13(4).
PMID: 37109077
Aim: To assess the efficacy of belimumab in joint and skin manifestations in a nationwide cohort of patients with SLE. Methods: All patients with skin and joint involvement enrolled in...
4.
Fasano S, Milone A, Nicoletti G, Isenberg D, Ciccia F
Nat Rev Rheumatol
. 2023 Apr;
19(6):331-342.
PMID: 37041269
Systemic lupus erythematosus (SLE) is an autoimmune disease that has diverse clinical manifestations, ranging from restricted cutaneous involvement to life-threatening systemic organ involvement. The heterogeneity of pathomechanisms that lead to...
5.
Ali S, Garcia C, Fasano S, Raine C, Wincup C
Rheumatol Adv Pract
. 2023 Mar;
7(1):rkad024.
PMID: 36874268
No abstract available.
6.
Fasano S, Messiniti V, Iudici M, Coscia M, Ciccia F
Lupus Sci Med
. 2023 Jan;
10(1).
PMID: 36631164
Background: Recent guidelines for SLE recommend using a hydroxychloroquine (HCQ) dose less than 5.0 mg/kg/day to reduce the risk of retinopathy. To determine if this dose reduction would have an...
7.
Wincup C, Fasano S
Rheumatology (Oxford)
. 2022 Jul;
62(2):492-494.
PMID: 35861392
No abstract available.
8.
Barbera L, Macaluso F, Fasano S, Grasso G, Ciccia F, Guggino G
Int J Mol Sci
. 2022 Jun;
23(12).
PMID: 35742974
The microbial community acts as an active player in maintaining homeostasis and immune functions through a continuous and changeable cross-talk with the host immune system. Emerging evidence suggests that altered...
9.
Fasano S, Iudici M, Coscia M, Messiniti V, Borgia A, Tirri R, et al.
Lupus Sci Med
. 2022 Mar;
9(1).
PMID: 35332100
Background: Patients with SLE have an endothelial dysfunction (ED), which is considered the earliest marker of cardiovascular (CV) disease. Endothelial cell activation induced by proinflammatory cytokines is defined by the...
10.
Ji L, Xie W, Fasano S, Zhang Z
Lupus Sci Med
. 2022 Jan;
9(1).
PMID: 34996857
Objective: Glucocorticoids (GC) withdrawal is part of the targets in current recommendations for SLE, but relapse is the most worrying issue. We aimed to investigate the predictors for flare in...